(2E)-4-OXOHEXADEC-2-ENOIC ACID


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YVMXUQKPIIUPBK-IERUDJENSA-M
Smiles	[Na+].CCCCCCCCCCCCC(=O)\C=C\C(=O)[O-]
InChI	InChI=1S/C16H28O3.Na/c1-2-3-4-5-6-7-8-9-10-11-12-15(17)13-14-16(18)19;/h13-14H,2-12H2,1H3,(H,18,19);/q;+1/p-1/b14-13+;

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H27NaO3
Molecular Weight	290.37
AlogP	5.37
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	13.0
Polar Surface Area	54.37
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	19.0

Assay Description	Organism	Bioactivity
Phytotoxicity against Solanum tuberosum cv. Desiree (potato) leaves at 1000 uM	Solanum tuberosum	None
Antioomycete activity against Phytophthora infestans isolate 208m2 infected potato plants assessed as decrease in fungal biomass at 100 uM applied on the abaxial leaf surface 2 hr prior to zoospore inoculation measured 3 days after fungal challenge by realtime PCR analysis	Phytophthora infestans	95.0 %
Antioomycete activity against Phytophthora infestans isolate 208m2 infected potato plants assessed as decrease in fungal biomass at 10 uM applied on the abaxial leaf surface 2 hr prior to zoospore inoculation measured 3 days after fungal challenge by realtime PCR analysis	Phytophthora infestans	80.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2230196
SureChEMBL	SCHEMBL2705509

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).